Navigation Links
Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
Date:4/16/2008

UCB announces clinical data presented at the 60th Annual Meeting of the

American Academy of Neurology (AAN) in Chicago

SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controlled clinical trials investigating lacosamide for the treatment of diabetic neuropathic pain. These data, which were presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago, showed that lacosamide significantly reduced pain in patients with diabetic neuropathic pain and was generally well-tolerated.

Lacosamide is currently under review with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of diabetic neuropathic pain and as adjunctive therapy for the treatment of partial onset seizures in adults with epilepsy.

"Neuropathy can be a painful and potentially debilitating complication of diabetes, and there is still a need for new treatment options," said Aziz Shaibani, M.D., F.A.C.P., lacosamide clinical investigator and director of the Nerve and Muscle Center of Texas in Houston. "These data showed that lacosamide reduced pain in patients with diabetic neuropathic pain and was generally well-tolerated."

Pooled Efficacy Analysis

Primary efficacy was evaluated among patients treated with 400 mg/day of lacosamide by examining the change in average daily pain score, from baseline to the last four weeks of maintenance in three Phase III, fixed-dose trials (SP742, SP743, SP768) and from baseline through the entire maintenance period in one Phase II, flexible-dose trial (SP614). The pain score was based on an 11-point Likert Scale ranging from zero (no pain) to 10 (worst possible pain).

The mean reduction in pain score reached the level of statistical significance in SP614, SP742 and SP768 (p=0.039, 0.01 and 0.0507, respectively). Significance was not
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ss., Nov. 30 According to Millenni...edical technology market intelligence, the nearly ...ned by almost 5% over 2008 as patients chose to de...c crisis. The market will, however, begin recovery...re-recession growth rates of over 15%. MRG,s facia...
(Date:11/30/2009)... 30 Minimally-invasive procedures ...y, particularly in oncology, cardiology and women,...mage-guided navigation expected to reach $600 mill...es offered by minimally-invasive procedures, inclu...nt comfort and faster patient throughput. ,, ...
(Date:11/30/2009)...ss., Nov. 30 Decision Resources, o...rms focusing on pharmaceutical and healthcare issu...et in Russia will grow nine percent annually over ...n by 2013. This growth will be driven mainly by in...eased use of more-expensive therapies like pegylat...
Breaking Medicine Technology:Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3Abilities Expo THE Event for People With Disabilities Is FREE and Happening THIS WEEK at the Schaumburg Convention Center 50059 1Abilities Expo THE Event for People With Disabilities Is FREE and Happening THIS WEEK at the Schaumburg Convention Center 50059 2Transave Receives 242 2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE 28TM 29 4650 1Transave Receives 242 2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE 28TM 29 4650 2Transave Receives 242 2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE 28TM 29 4650 3Transave Receives 242 2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE 28TM 29 4650 4Effective pain treatment for cancer patients 3F 50057 1Effective pain treatment for cancer patients 3F 50057 2
(Date:11/30/2009)... 1 Results of a randomized, contro...meeting of the Radiological Society of North Ameri...rrowing or blockage in arteries that supply blood ...significant but silent coronary artery disease. ,... plaque, a combination of fat, cholesterol and oth...
(Date:11/30/2009)...Nov. 30 HealthPlus of Michigan tod...icarePlus plans designed for Medicare-eligible pe...nvenient access to quality health care. ,, Hea...care plans in Michigan, according to the "America,... U.S. News & World Report and the National Com...
(Date:11/30/2009)...dministrator Alonzo L. Fulgham ,, WASHINGTON, ..., the global community once again recognizes World...V/AIDS worldwide. This is also a time to renew ou...s epidemic and pay homage to the millions of peopl...ajor partner in the U.S. President,s Emergency Pla...
(Date:11/30/2009)...v. 30 Major League Baseball,s Ma...ity Royals and recently acquired by the Chicago Wh.... The award is given annually to a Major League Ba...age and dedication of baseball great Fred Hutchins...r-old Redlands, Calif., native made his MLB debut ...
(Date:11/30/2009)...out treatment for blood-borne diseases, researcher...s) -- Many medical students get stuck by needles, ... they often fail to alert hospital authorities, wh... has found. , The researchers interviewed 699 s...hat 415 -- 59 percent -- had experienced needlesti...
Breaking Medicine News(10 mins):Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 2Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 3Health News:HealthPlus Launches New Medicare Advantage Plans 2Health News:HealthPlus Launches New Medicare Advantage Plans 3Health News:USAID Recognizes World AIDS Day 2Health News:Mark Teahen Named 2009 Hutch Award Winner 2Health News:Med Students Often Fail to Report Needlestick Injuries 2
...WA and POZ reinvigorate AIDS activism - , , WASHI... with AIDS (NAPWA) and POZ magazine today announ...nver Principles Project. The project aims to enco... HIV/AIDS -- with the ultimate goal of strengtheni...
...effective communication are the root causes , , R...ho live in rural areas are at greater risk of club...al populations, and researchers are beginning to u...ural differences and communication barriers are fa...
...illy USA Business-to-Business Organization and Ove...Bailey,s Leadership Role Expands to Include Lilly ...h 2 Eli Lilly and Company (NYSE: LLY ) today an...U.S. Business-to-Business organization. As vice pr...
...r.com,( http://www.himfr.com/hot-products/ ), on...e than 30 B2B industry websites to its name, recom...Cherry: , Cherry ( http://www.himfr.com/buy-c...ar ( http://www.himfr.com/buy-pear/ ),or orange,...
...rica with NightWave sleep device , , PORTLAND, Or...Week, Coherence Resources, Inc. provided Peace Cor...y need: adequate sleep. Malaria medications taken...olunteers are facing a lot of challenges over ther...
...tio of topical agents for patients with mild to mo...he American Academy of Dermatology (Academy) has r...and treatment of psoriasis with topical therapies ...of six sections of the guidelines of care for psor...
Other Medicine News:Health News:The National Association of People with AIDS (NAPWA) and POZ Magazine Partner to Launch The Denver Principles Project 2Health News:The National Association of People with AIDS (NAPWA) and POZ Magazine Partner to Launch The Denver Principles Project 3Health News:Native American Children are at Greater Risk for Clubfoot Recurrence 2Health News:Native American Children are at Greater Risk for Clubfoot Recurrence 3Health News:Lilly Announces Leadership Changes 2Health News:Lilly Announces Leadership Changes 3Health News:Himfr.com Recommends Five Foods for Spring 2Health News:Sleepless in Botswana 2Health News:Sleepless in Botswana 3Health News:American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies 2Health News:American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies 3Health News:American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies 4Health News:American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies 5Health News:American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies 6
...tive determination of Estradiol (E2) concentration... steroid hormone with a phenolic A ring. This ste...is the most potent natural Estrogen, produced main...by the adrenal cortex, and the male testes. Estrad...
Human Cardiac-Specific Troponin-I Enzyme Immunoassay (cTnI ELISA)
Innotrac Aio! 2nd Generation Troponin I Assay
... a high-throughput immunoassay system built around...000 with the important addition of Logic Driven In... be designed for optimal performance with the fast...critical assays such as the cardiac biomarkers and...
Medicine Products: